Treatment for all: a vision for the future

Summary  The World Federation of Hemophilia (WFH) has defined a new strategic plan which maps out where the organization is going and what it can do for our members. The plan embraces the vision of Treatment for All; i.e. one day, treatment will be available for all those with inherited bleeding disorders, regardless of where they live. Treatment for All means proper diagnosis, management, and care by a multidisciplinary team of trained specialists. It means safe, effective treatment products are available for all people with inherited bleeding disorders. It means expanding services beyond haemophilia, to those with von Willebrand's disease, rare factor deficiencies, and inherited platelet disorders. Today, more than 75% of the global bleeding disorders community receive either inadequate or no treatment whatsoever. Our mission is to improve treatment where it is limited or does not exist. At the same time, we must sustain the many gains we have achieved thus far. The challenge is immense. Making our vision a reality requires us to be focused and deliberate about the programmes we undertake and the commitments we make. Building on past strategic plans, this plan presents a vision for the continued success of the WFH over the next 3–5 years.     

An interpretation of14C-urea and14C-primidone extraction in isolated rabbit lungs

We measured the venous concentration versus time curves of¹⁴C-urea and¹⁴C-primidone after rapid bolus injections of a vascular reference indicator, fluorescein isothiocyanate dextran, and one of the two¹⁴C-labeled indicators in isolated rabbit lungs perfused with Krebs-Ringer bicarbonate solution containing 4.5% bovine serum albumin at flow rates (F) of 6.67, 3.33, 1.67, and 0.83 ml/sec and with nearly constant microvascular pressure and total lung vascular volume. When we calculated the permeability-surface area product,PS, from the¹⁴C-urea and¹⁴C-primidone outflow curves using the Crone model, the estimates of thePS product were directly proportional toF. However, the fractional change in thePS with flow was different for the two indicators. We also estimated thePS from the same¹⁴C-urea and¹⁴C-primidone data using an alternative model that includes perfusion heterogeneity, estimated in a previous study, and flow-limited and barrier-limited extravascular volumes accessible to both urea and primidone. This model was able to fit the outflow curves of either¹⁴C-urea or¹⁴C-primidone at all four flows studied with one flow-independentPS for each indicator. The ability of the new model to explain the¹⁴C-urea and¹⁴C-primidone data with no flow-dependent change inPS suggests that a change inPS withF estimated using other models such as the Crone model is not sufficient evidence for capillary surface area recruitment.     

山楂炮制品的工艺及质量研究

本文通过非水滴定法、比色法、胃肠推进运动实验法对山楂炒制法和烘制法工艺及其炮制品的质量进行了研究。     

NDPK／nm23在胆囊,胆管癌中的表达及临床意义

用免疫组化ABC法对41例胆囊癌、12例胆管癌NDPK／nm23表达进行了测定。结果发现：nm23在恶性肿瘤中的表达率明显高于良性病变（P＜0．05）。NDPK／nm23表达与胆囊及胆管癌组织的分化、局部浸润及淋巴转移密切相关（P＜0．05），提示nm23检测对正确估计肿瘤的侵袭性、淋巴转移潜能及预后有重要价值。     

急性白血病者纤维蛋白原和纤维蛋白降解产物的变化与DIC的关系

本文对45例急白患者的Fbg、FDP进行测定,并同时做3P试验,还对其中15例于治疗后进行复查,发现急白患者Fbg和FDP水平比正常组高,其平均值分别为369 ± 39mg％和168.0 ± 241.3μg/ml(正常对照组两者分别为269 ± 39mg％和<10μg/ml)。对15例治疗后的复查表明,治疗前后的Fbg和FDP没有统计学意义。作者认为诊断急白并发DIC时,对Fbg和FDP以及3P试验的诊断价值应认真加以考虑。     

Statistical Methodology

Survival analysis is a group of statistical methods used to analyze data representing the time to an event of interest, e.g., the duration of survival after an out-of-hospital cardiac arrest or the length of time a patient stays in the ED. Survival analysis properly accounts for patients who are lost to follow-up and for patients who have not yet experienced the event of interest at the end of the study's observation period (censored data). This article acquaints the reader with the terminology, methodology, and limitations of survival analysis. Specific methods discussed include life tables, the Kaplan-Meier product limit estimate, the log-rank test, and the multivariate Cox proportional hazards model.     

盐酸蒽丹西酮的杂质及降解产物的合成和分析方法研究

根据几种不同的合成路线分析了产品中可能存在的五种杂质及降解产物Ⅱ、Ⅲ、Ⅳ、Ⅴ和Ⅵ，并合成了Ⅱ、Ⅲ和Ⅳ。用氰基柱反相高效液相色谱法进行了测定，获得了良好的分离效果，从而建立了控制盐酸蒽丹西酮质量的方法。     

尼索地平光解产物的制备及药理作用

本文报道了尼索地平光解产物的制备及其药理和毒性实验。结果表明:给家兔静脉注射光解产物,有微弱而短暂的降压作用,给小鼠灌胃无任何毒性,而腹腔注射则有一些毒性,故尼索地平注射剂中应严格控制光解产物的含量。